Hayato Kawachi

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Radiation Therapy

Cross Sectional

Top Venues

Therapeutic advances in medical oncology

Molecular cancer therapeutics

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Takayuki Shimose, Koichi Takayama
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study). Therapeutic advances in medical oncology 15 (2023)
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Tadaaki Yamada, Nobuyo Tamiya, Naoko Okura, Takahiro Yamada, Junji Murai, Shinsuke Shiotsu, Takayasu Kurata, Takayama Koichi
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers 15 (20) (2023)
Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Masaki Ishida, Hayato Kawachi, Yohei Matsui, Ryota Nakamura, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Yoshitaka Sekido, Shinsaku Tokuda, Takayama Koichi
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular cancer therapeutics (2023)
Hayato Kawachi, Motohiro Tamiya, Kinnosuke Matsumoto, Akihiro Tamiya, Takafumi Yanase, Satoshi Tanizaki, Toru Kumagai
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. Investigational new drugs 40 (3) (2022)